S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
3 Value Stocks Too Small For Buffett’s Portfolio
Stock market today: Asian shares are mostly higher after another set of Wall St records
Foot Locker Builds Up Another Head of Steam; Gains Imminent
Disney Stock Catches 3 Upgrades In a Single Week
Average long-term US mortgage rate falls slightly, easing borrowing costs for home shoppers
Walgreens books hefty charge as the drugstore chain adjusts the value of struggling clinics
Algeria's government pushes staples to subsidized markets to stave off Ramadan shortages
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
3 Value Stocks Too Small For Buffett’s Portfolio
Stock market today: Asian shares are mostly higher after another set of Wall St records
Foot Locker Builds Up Another Head of Steam; Gains Imminent
Disney Stock Catches 3 Upgrades In a Single Week
Average long-term US mortgage rate falls slightly, easing borrowing costs for home shoppers
Walgreens books hefty charge as the drugstore chain adjusts the value of struggling clinics
Algeria's government pushes staples to subsidized markets to stave off Ramadan shortages
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
3 Value Stocks Too Small For Buffett’s Portfolio
Stock market today: Asian shares are mostly higher after another set of Wall St records
Foot Locker Builds Up Another Head of Steam; Gains Imminent
Disney Stock Catches 3 Upgrades In a Single Week
Average long-term US mortgage rate falls slightly, easing borrowing costs for home shoppers
Walgreens books hefty charge as the drugstore chain adjusts the value of struggling clinics
Algeria's government pushes staples to subsidized markets to stave off Ramadan shortages
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
3 Value Stocks Too Small For Buffett’s Portfolio
Stock market today: Asian shares are mostly higher after another set of Wall St records
Foot Locker Builds Up Another Head of Steam; Gains Imminent
Disney Stock Catches 3 Upgrades In a Single Week
Average long-term US mortgage rate falls slightly, easing borrowing costs for home shoppers
Walgreens books hefty charge as the drugstore chain adjusts the value of struggling clinics
Algeria's government pushes staples to subsidized markets to stave off Ramadan shortages
NASDAQ:GRTX

Galera Therapeutics (GRTX) Stock Price, News & Analysis

$0.14
-0.01 (-6.67%)
(As of 03/28/2024 ET)
Today's Range
$0.13
$0.19
50-Day Range
$0.14
$0.27
52-Week Range
$0.09
$3.59
Volume
4.31 million shs
Average Volume
880,536 shs
Market Capitalization
$7.61 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
GRTX stock logo

About Galera Therapeutics Stock (NASDAQ:GRTX)

Galera Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the transformation of radiotherapy in cancer. The company's lead product candidate is avasopasem manganese (GC4419), a small molecule dismutase mimetic, which has completed Phase III clinical trial for the treatment of radiotherapy induced severe oral mucositis in patients with head and neck cancer (HNC); in Phase IIa clinical trial for the treatment of radiotherapy-induced esophagitis in patients with lung cancer; and in Phase IIa clinical trial for patients with HNC undergoing standard-of-care radiotherapy. It is also developing GC4711, a dismutase mimetic product candidate, which is in Phase I/II clinical trial in combination with stereotactic body radiation therapy in patients with non-small cell lung cancer and locally advanced pancreatic cancer. The company was incorporated in 2012 and is based in Malvern, Pennsylvania.

GRTX Stock Price History

GRTX Stock News Headlines

Trump’s “Tax Free” Retirement Strategy
Since 1924 — over one hundred years — the US dollar has lost nearly 18x its value. In other words, a dollar back then would buy $17.82 worth of goods in today's money. If you're planning on retiring any time soon…This poses a real problem.
GRTX Apr 2024 0.500 call
Galera Therapeutics, Inc. (GRTX)
Galera Therapeutics, Inc.
Galera Therapeutics Inc (GRTX)
Trump’s “Tax Free” Retirement Strategy
Since 1924 — over one hundred years — the US dollar has lost nearly 18x its value. In other words, a dollar back then would buy $17.82 worth of goods in today's money. If you're planning on retiring any time soon…This poses a real problem.
Galera Therapeutics: Q3 Earnings Insights
Galera Therapeutics's Earnings Outlook
US Stocks Fall; Pfizer Swings To Q3 Loss
Galera Therapeutics (GRTX) Gets a Hold from H.C. Wainwright
See More Headlines
Receive GRTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Galera Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/10/2021
Today
3/29/2024
Next Earnings (Estimated)
5/09/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:GRTX
Fax
N/A
Employees
31
Year Founded
N/A

Profitability

Net Income
$-62,220,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
($3.83) per share

Miscellaneous

Free Float
50,639,000
Market Cap
$7.61 million
Optionable
Optionable
Beta
2.23
The 10 Best AI Stocks to Own in 2024 Cover

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Key Executives

  • Dr. J. Mel Sorensen M.D. (Age 67)
    CEO, President & Director
    Comp: $908.35k
  • Mr. Christopher Degnan (Age 44)
    Chief Financial Officer
    Comp: $603.52k
  • Dr. Robert A. Beardsley M.B.A. (Age 63)
    Ph.D., Co-Founder & COO
    Comp: $627.52k
  • Ms. Jennifer Evans Stacey Esq. (Age 59)
    Chief Legal & Compliance Officer and Secretary
  • Ms. Andie Collier
    Chief Regulatory & Quality Affairs Officer
  • Ms. Judy Schnyder
    Senior Vice President of Clinical Operations & Data Management

GRTX Stock Analysis - Frequently Asked Questions

Should I buy or sell Galera Therapeutics stock right now?

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Galera Therapeutics in the last year. There are currently 1 sell rating and 3 hold ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "reduce" GRTX shares.
View GRTX analyst ratings
or view top-rated stocks.

How have GRTX shares performed in 2024?

Galera Therapeutics' stock was trading at $0.1454 at the start of the year. Since then, GRTX stock has decreased by 3.7% and is now trading at $0.14.
View the best growth stocks for 2024 here
.

Are investors shorting Galera Therapeutics?

Galera Therapeutics saw a decline in short interest in March. As of March 15th, there was short interest totaling 2,800,000 shares, a decline of 45.0% from the February 29th total of 5,090,000 shares. Based on an average daily trading volume, of 1,980,000 shares, the short-interest ratio is presently 1.4 days. Currently, 7.3% of the company's stock are sold short.
View Galera Therapeutics' Short Interest
.

When is Galera Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024.
View our GRTX earnings forecast
.

How were Galera Therapeutics' earnings last quarter?

Galera Therapeutics, Inc. (NASDAQ:GRTX) released its quarterly earnings results on Wednesday, November, 10th. The company reported ($0.86) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.71) by $0.15.

What other stocks do shareholders of Galera Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Galera Therapeutics investors own include Fulcrum Therapeutics (FULC), Ardelyx (ARDX), Chiasma (CHMA), Provention Bio (PRVB), Seelos Therapeutics (SEEL), Soligenix (SNGX), TG Therapeutics (TGTX) and VBI Vaccines (VBIV).

When did Galera Therapeutics IPO?

Galera Therapeutics (GRTX) raised $75 million in an IPO on Thursday, November 7th 2019. The company issued 5,000,000 shares at $14.00-$16.00 per share. BofA Merrill Lynch, Citigroup and Credit Suisse acted as the underwriters for the IPO and BTIG was co-manager.

Who are Galera Therapeutics' major shareholders?

Galera Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include GSA Capital Partners LLP (7.16%), abrdn plc (1.65%), Vanguard Group Inc. (0.82%), Vanguard Group Inc. (0.82%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Chris Degnan, Linda West, Mark Bachleda and Mel Sorensen.
View institutional ownership trends
.

How do I buy shares of Galera Therapeutics?

Shares of GRTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:GRTX) was last updated on 3/29/2024 by MarketBeat.com Staff

From Our Partners